Treating Acutely Agitated Patients With Asenapine Sublingual Tablets: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Treating Acutely Agitated Patients With Asenapine Sublingual Tablets (NCT01400113), a randomized phase 4 study. The primary outcome is Positive and Negative Syndrome Scale - Excited Component.

2. Clinical Question

The study is described as a single-dose, randomized, double-blind, placebo-controlled trial. Its primary outcome was the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC), a measure focused on agitation-related symptoms. The registry describes five components: excitement, tension, hostility, uncooperativeness, and poor impulse control. Each item is rated from 1, meaning not present, to 7, meaning extremely severe. Total scores range from 5 to 35, and mean scores of 20 or higher are described as corresponding clinically to severe agitation.

The clinical question is narrow in time and scope: it concerns a single administration and the recorded change over 2 hours, not longer-term symptoms or repeated treatment. The registry also lists the Clinical Global Impression Scale as a secondary outcome, but does not post a numerical result for it. The primary result gives an arm-specific mean and confidence interval for each treatment group; the registry does not provide a reported treatment-effect estimate or test of the difference between groups.

3. Trial Design

The registry identifies this as a Phase 4, randomized, parallel-group trial with quadruple masking. It describes the trial as single-dose, double-blind, and placebo-controlled. The masking label is reported as quadruple, but the registry does not identify which roles were masked or describe the masking procedures. The sponsor is Unity Health Toronto. The study status is completed; the recorded start is 2012-04 and primary completion is 2012-12.

The interventions were asenapine and placebo, both listed as drugs. The asenapine arm received 10mg sublingually as a single dose; the placebo arm received a single sublingual dose. The registry enrollment is 120. For the primary outcome, the posted arm-level counts are 59 for asenapine and 59 for placebo. Those outcome counts should not be treated as an explanation of enrollment or as proof of how many participants were randomized, completed treatment, or entered a particular analysis population; those details are not reported in the registry record.

The parallel design assigns participants to one of the treatment arms rather than describing repeated treatment periods within participants. Randomization is reported, but the sequence-generation method, allocation concealment, stratification, and any planned adjustment variables are not reported in the registry record. The record also does not describe the intended sample-size justification or give a protocol-level account of the statistical analysis plan.

The primary outcome is change in PANSS-EC from baseline to 2 hours after drug or placebo administration. The listed secondary outcome is the Clinical Global Impression Scale. Although two outcome measures are recorded, only one secondary outcome is named in the registry summary, and no numerical secondary result is posted. The registry lists no analyses. As a result, the design features identify the intended randomized comparison, but the posted results do not include an adjusted or unadjusted estimate comparing the assigned groups.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Positive and Negative Syndrome Scale - Excited Component, measured over Change in PANSS-EC score from baseline to 2 hours post drug/placebo administration..

The primary endpoint is the change in Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) score from baseline to 2 hours after administration. PANSS-EC is intended to capture agitation-related symptoms through five items: excitement, tension, hostility, uncooperativeness, and poor impulse control. Each item is rated from 1, not present, to 7, extremely severe, giving a total score range from 5 to 35. The registry states that mean scores of 20 or higher correspond clinically to severe agitation.

A change score focuses on movement from a participant’s starting measurement over a specified interval, rather than solely on the score at the later assessment. Such an endpoint can be useful when the clinical question concerns short-term symptom change after an intervention. The 2-hour timeframe makes this a measure of an acute response window; it does not describe persistence beyond that assessment.

The registry reports an arm-specific mean and 95% confidence interval for the endpoint. It does not explain the sign convention for the reported change values, such as whether a positive value denotes an increase or decrease from baseline. Although the scale’s item ratings indicate greater symptom severity at higher values, interpreting the direction of the posted change means requires knowing how change was coded. That coding detail is not reported in the registry record.

The endpoint is continuous, so its mean summarizes the average recorded change within an arm. A mean does not show the full distribution of individual responses or how many participants improved, worsened, or had no change. Those details are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

A randomized parallel-group trial is designed to compare groups assigned to different interventions. Random assignment can support a causal comparison by reducing systematic differences in expected characteristics between groups, but the strength of the inference also depends on how the trial was conducted and analyzed. The registry identifies randomization and a parallel model; the sequence-generation and allocation-concealment procedures are not reported in the registry record.

What does an arm mean estimate?

For a continuous outcome, an arm mean is the average observed value among the participants included in that arm’s analysis. In this trial, the endpoint is change in PANSS-EC score from baseline to 2 hours. The registry reports mean changes of 7.86 for asenapine and 14.93 for placebo. Those figures describe the recorded arm summaries. They do not, on their own, quantify the randomized treatment effect, which would ordinarily be expressed as a contrast between groups.

The registry lists 59 participants for each arm’s primary outcome. The analysis population behind those counts is not described. In particular, the registry does not state whether the means include everyone randomized, only participants with observed follow-up, or another defined group. The distinction matters because the interpretation of a randomized comparison depends on how participants are retained in the analysis and how missing measurements are handled.

What does a confidence interval communicate?

A confidence interval describes the uncertainty associated with an estimated quantity under a statistical model and its assumptions. The registry reports 95% confidence intervals for each arm’s mean: 2.06 to 13.66 for asenapine and 7.69 to 22.17 for placebo. These intervals concern the separate arm means. They do not directly provide the uncertainty around a difference between means. A formal comparison would require an estimate of that difference and its uncertainty, neither of which is posted.

Confidence intervals should not be interpreted as containing a fixed proportion of individual participants’ scores. They are also not proof that the true value lies within the displayed limits. They provide a framework for judging the precision of an estimate, conditional on the method used. The registry identifies the interval type as 95% confidence intervals, but does not describe the method used to calculate them.

Why is the comparison result important?

The study question is comparative because participants were assigned to asenapine or placebo. A direct treatment contrast would ordinarily show how far apart the group results are, together with uncertainty for that contrast. The registry reports no analysis for the continuous two-arm comparison and states that values are missing or not estimable for such a comparison. Consequently, no p-value, contrast estimate, or contrast confidence interval is available in the registry record. It would be inappropriate to substitute a calculation based only on the posted arm summaries for the trial’s own analysis.

A comparison can be adjusted or unadjusted. An unadjusted contrast uses the outcome data without incorporating other covariates; an adjusted analysis includes specified variables, often to account for baseline values or design features. Whether an adjusted model was planned or used is not reported in the registry record. The record does not provide enough information to determine whether any additional analysis was performed outside the posted results.

What does planning based on an observed effect mean?

A sample-size planning illustration uses assumptions to explore how many participants per arm might be needed to detect an effect under a chosen design and statistical approach. The registry’s planning description refers to a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the target effect expressed as a fraction of the observed effect. Such an illustration is hypothetical: it is not the trial’s observed power, and it does not demonstrate that the completed trial had adequate power. The registry record does not report the trial’s own sample-size justification. No planning counts or target-effect fractions are stated in the registry information used for this interpretation.

General statistical context: a planning calculation depends on assumptions about the effect to detect, variability, allocation, and the chosen error rate. If an observed effect is used as the starting point, the resulting figures can be sensitive to how representative that estimate is. A planning illustration should therefore be distinguished from a prespecified design rationale and from an analysis of the completed trial.

Why can variability affect interpretation?

Continuous outcomes vary between participants. Greater variability generally makes a mean less precise for a fixed amount of information, while lower variability tends to support greater precision. The posted confidence intervals communicate uncertainty about the arm means, but the registry does not report a standard deviation or other dispersion measure for the outcome. The interval calculation method and assumptions are also not described.

General statistical context: over-dispersion occurs when observed variability is greater than expected under a model. When a model does not account for excess variability, standard errors can be too small and intervals or tests can appear more precise than warranted. No over-dispersion assessment is reported for this trial, and the posted outcome is a continuous measure rather than a reported count model. This general issue should not be mistaken for evidence that over-dispersion occurred in the trial.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists the PANSS-EC change as the primary outcome and the Clinical Global Impression Scale as a secondary outcome. It also records two outcome measures, but only one secondary outcome is named in the summary. No numerical result for the secondary outcome is posted. The registry does not report how many statistical hypotheses were planned across outcomes, time points, or other analyses, or whether any adjustment for multiple testing was planned or applied. This information is not reported in the registry record.

Multiplicity matters when several hypotheses are tested, because the chance of at least one apparently notable result can increase as the number of tests grows. This is general statistical context, not a claim that the trial conducted multiple tests. The registry lists zero analyses, so it does not provide test results from which to assess how multiplicity was handled.

The record gives outcome counts of 59 in each arm, but does not describe missing baseline or follow-up measurements, withdrawals, exclusions, or reasons for missing data. It does not say whether missing outcomes were imputed, handled using a model, or excluded from the analysis. The relation between the registry enrollment of 120 and the posted outcome counts is not explained. Missing-data handling and participant flow are therefore not reported in the registry record.

The analysis population is also unspecified. The registry does not say whether the primary endpoint was analyzed according to randomized assignment, treatment received, or another population definition. Nor does it describe protocol deviations or any sensitivity analysis. These omissions limit assessment of whether the posted means preserve the intended randomized comparison and how robust the results might be to missing observations or alternative analysis choices.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry reports zero participants with a serious adverse event in the asenapine group and zero in the placebo group. The serious-event risk counts are 60 for each arm. It also reports zero participants with other adverse events in each group, with other-event risk counts of 60 for each arm. These are event summaries as recorded in the registry; they are not a statistical comparison between arms.

Zero reported affected participants does not establish that no adverse events could occur, nor does it establish equivalence between treatments. The record does not provide definitions for serious and other adverse events, the period over which they were collected, severity details, or the method for attributing events to treatment. The number of deaths is not reported in the registry record; the death entries are not given as numerical counts.

The safety risk counts differ from the posted primary-outcome counts, which are 59 in each arm. The registry does not explain that difference or specify whether the same analysis population and follow-up coverage apply to both sets of results. These safety figures should therefore be read as the posted group counts, without inferring why the denominators differ or how complete event collection was.

12. What the Result Does, and Does Not, Mean

The registry supports a limited description of the observed primary outcome: mean PANSS-EC change was 7.86 in the asenapine arm and 14.93 in the placebo arm, with separate 95% confidence intervals. It does not report a statistical comparison of those means. The arm summaries alone cannot establish the size, precision, or statistical significance of a treatment effect.

The endpoint is a short-term measure of change from baseline to 2 hours. It does not describe later outcomes or whether any change persisted. The registry gives the scale’s symptom content and scoring range, but not the sign convention for the reported change values. Without that convention, the numerical direction of the reported means cannot safely be translated into a statement about improvement or worsening.

The record also does not report a numerical secondary-outcome result for the Clinical Global Impression Scale. It provides no analysis details for the primary outcome, no estimate of the between-arm contrast, and no account of how missing data or analysis populations were handled. The record’s completed status and enrollment figure do not fill those gaps.

These results do not establish that asenapine works or does not work for acute agitation. They describe posted arm-level outcome summaries and identify important analysis information that is unavailable in the registry record. The safety summary reports zero affected participants for serious and other adverse events in both groups, but without event definitions, collection details, or a comparative analysis, those counts cannot establish a broader safety conclusion.

General statistical context: a treatment conclusion in a randomized trial ordinarily depends on a direct comparison, its uncertainty, the endpoint’s clinical meaning, and the credibility of the analysis. An isolated group mean is not a substitute for that comparison. The posted results should therefore be interpreted as incomplete evidence about the trial’s comparative question, rather than as a definitive answer.

13. Why This Trial Matters Statistically

This trial illustrates the distinction between reporting outcomes by arm and reporting a randomized treatment comparison. The registry gives a mean and 95% confidence interval for each group’s PANSS-EC change, but lists no analyses and does not provide an estimated difference between groups. Readers can see the arm-specific summaries, yet cannot assess the reported precision of the primary comparison because that comparison is absent.

It also highlights the importance of making outcome definitions operational. The record identifies change from baseline to 2 hours, describes the PANSS-EC items, and gives the scale range. It does not state the sign convention for change. That small but essential interpretive detail determines how a positive mean change should be understood. The endpoint description alone does not settle the direction of the posted values.

The difference between the outcome counts and the safety risk counts is another reason to keep denominators tied to the specific result being read. The primary outcome counts are 59 in each arm, while the safety risk counts are 60 in each arm. The registry does not explain the distinction. Reporting clear participant flow and analysis populations would help readers understand which observations contribute to each result.

Finally, the record lists a secondary outcome without posting its numerical result and does not describe multiplicity procedures, missing-data methods, or the sample-size justification. These are not merely technical details: they shape how much confidence can be placed in a result and whether different outcomes have been interpreted consistently. The trial matters statistically as an example of why complete comparative estimates, prespecified methods, and transparent outcome reporting are necessary for readers to evaluate clinical-trial evidence.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most direct limitation of the posted results is the absence of an inferential comparison for the primary continuous outcome. The registry provides arm-level means and confidence intervals but no treatment-effect estimate, confidence interval for the contrast, or p-value. It identifies the two-arm comparison as not estimable in the posted results, so the primary randomized question is not answered by a reported comparative analysis.

The registry does not describe the sign convention for the change scores. This prevents a confident reading of whether the positive mean values correspond to increases or decreases from baseline. Baseline scores and arm-level follow-up scores are also not reported, so the change summaries cannot be checked against those components.

Information about participant flow, analysis populations, missing observations, and missing-data methods is not reported in the registry record. Outcome counts are 59 in each arm, whereas safety risk counts are 60 in each arm; the reason for that difference is not given. These omissions make it difficult to assess completeness and the relationship between the recorded results and the randomized groups.

The registry does not report the randomization sequence method, allocation concealment, masking procedures, protocol deviations, or prespecified analysis details. It lists the Clinical Global Impression Scale as a secondary outcome but does not post its numerical result. Multiplicity handling and the trial’s own sample-size justification are not reported. The posted safety figures also lack event definitions and collection details, and the death counts are not reported in the registry record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Treating Acutely Agitated Patients With Asenapine Sublingual Tablets — NCT01400113.
• Registry record last updated 2016-05-16; status last verified 2016-04.
• Results first posted 2016-05-16.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The record describes a completed Phase 4 randomized, parallel-group, quadruple-masked trial of a single sublingual dose of asenapine versus a single sublingual placebo dose for acute agitation. It lists enrollment of 120 and records a study start of 2012-04 and primary completion of 2012-12. The primary outcome is PANSS-EC change from baseline to 2 hours.

The registry posts arm-specific mean changes and 95% confidence intervals, with outcome counts of 59 in each group, but no statistical analysis comparing the groups. The Clinical Global Impression Scale is listed as a secondary outcome without a posted numerical result. Serious and other adverse-event counts are reported as zero affected participants in each arm; death counts are not reported in the registry record.

Important interpretive details—including change-score direction, analysis population, missing-data handling, and the statistical method—are not reported in the registry record.